-
Meeting of the Board of Directors of Valerio Therapeutics S.A. on November 13, 2024
Meeting of the Board of Directors of Valerio Therapeutics S.A. on November 13, 2024
Share
PARIS--(BUSINESS WIRE)--Regulatory News:
At its meeting of November 13, 2024, the Board of Directors of Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO), (“Valerio Therapeutics” or the “Company”) decided to appoint Mr Julien Miara as CEO and Chairman of the Board of Valerio Therapeutics, succeeding Ms Shefali Argawal, effective immediately.
Future evolutions related to the Company’s governance will be announced at a later date.
Contacts
Valerio Therapeutics
Investor Relations
ir@valeriotx.com
France: +33 (0) 1 70 38 33 99
U.S.: +1 617 366 1022
More News From Valerio Therapeutics S.A.
Valerio Therapeutics Announces Development Collaboration with Abivax and Provides Pipeline Update
VILLEJUIF, France--(BUSINESS WIRE)--Regulatory News: Valerio Therapeutics (FR0010095596 – ALVIO), a biotechnology company pioneering next-generation precision-guided RNA therapeutics (“Valerio” or the “Company”), today announces that it has entered into a binding term-sheet with Abivax SA (“Abivax”), setting out the principal terms of an exclusive worldwide research and development collaboration. The final terms remain subject to the signing of the definitive co-ownership and license agreement....
Valerio Therapeutics Announces Binding Offer for the Proposed Acquisition of Etherna Immunotherapies, Creating a Global Leader in Targeted RNA Medicines
VILLEJUIF, France--(BUSINESS WIRE)--Regulatory News: Valerio Therapeutics (FR0010095596 – ALVIO), a biotechnology company pioneering next-generation precision-guided RNA therapeutics ("Valerio" or the "Company"), today announces that it has signed a binding offer for the acquisition of 100% of the share capital of Etherna Immunotherapies NV ("Etherna") (the "Acquisition"). Etherna is a leading technology platform company pioneering the development of mRNA and lipid nanoparticle (LNP) technologi...
Valerio Therapeutics Appoints Gilles Besin as Chief Executive Officer and Announces Results of its Annual General Meeting
VILLEJUIF, France--(BUSINESS WIRE)--Regulatory News: Valerio Therapeutics (FR0010095596 – ALVIO), a clinical-stage biotechnology company pioneering next-generation precision-guided therapeutics (the "Company"), today announces the appointment of Gilles Besin, Ph.D. as Chief Executive Officer by the Board of Directors, effective 1 July 2026, as well as the results of the votes at its shareholders’ general meeting held on 16 June 2026 (the "General Meeting"). The General Meeting approved all reso...